Aldosterone Antagonist Therapy for Adults With Heart Fail... | NCT00094302

ID	Type	Description	Link
HHSN268200425207C	Other Grant/Funding Number	NIH contract

Status Module

Name	Class
National Heart, Lung, and Blood Institute (NHLBI)	NIH

Description Module

Detailed Description

BACKGROUND:

Heart failure (HF) is a major cause of morbidity and mortality, particularly in older people. Indeed, it is the most common discharge diagnosis in patients older than 65 years. As the United States population ages, heart failure will continue to grow as a public health concern. Therapeutic trials of heart failure have dealt almost exclusively with patients who have systolic dysfunction. However, there is now an emerging awareness that nearly half of the patients with heart failure have preserved systolic function and that the survival of these patients is adversely affected. This study is a randomized clinical trial of a novel therapeutic approach, specifically the use of spironolactone, an aldosterone antagonist, in treating these patients. While this treatment has been shown to be useful in treating heart failure with reduced systolic function, it has not been studied in patients with preserved systolic function.

Patients with heart failure and preserved systolic function have a poor prognosis. The annual mortality rate is intermediate between the prognosis for those without heart failure and for those with heart failure and reduced systolic function. For instance, Family Health Study participants with heart failure and preserved systolic function had a mortality rate of 9% compared to 3% for their age- and gender-matched controls. The mortality rate was 19% in heart failure patients with reduced systolic function heart failure compared to 4% for their matched controls.

As heart failure develops, neurohormones are released that initially improve cardiac output but ultimately contribute to progression of left ventricular dysfunction. The renin-angiotensin-aldosterone system is an important part of this compensatory response. Aldosterone levels may rise to 20 times normal levels in heart failure and aldosterone contributes to the development of myocardial fibrosis. Spironolactone is a potassium-sparing diuretic that acts on the distal tubule, inhibiting sodium and potassium ion exchange. There are several potential beneficial actions, including prevention of cardiac fibrosis. A recent trial evaluated spironolactone in patients with systolic dysfunction heart failure. Spironolactone treatment caused a 30% reduction in mortality compared to placebo (p< 0.001). The improvement resulted from a reduction in all cause mortality. More recently, the Eplerenone Post-Myocardial Infarction (MI) study showed that this aldosterone antagonist significantly reduces mortality despite background treatment with an angiotensin-converting enzyme (ACE) inhibitor and beta-blocker. Advantages of using spironolactone in this study are that it is commercially available, inexpensive, and no longer under patent (therefore this study will not be done by industry). Also, there is a clear physiologic rationale for its use, and the side effect profile is well understood. The study enrolled subjects who had preserved systolic function with heart failure and who met clearly defined eligibility criteria that were selected to make the results widely generalizable to clinical practice.

DESIGN NARRATIVE:

This is a randomized, double-blinded, placebo-controlled trial of aldosterone antagonist therapy (15 mg dose spironolactone or placebo; titrated up to 30 or 45 mg/day) in 3,445 adult patients with heart failure and preserved systolic function. Patients were recruited from August 2006 through January 2012, treated, and will be followed through June 2013. Approximately 270 clinical sites in six countries were subcontracted by the clinical trial coordinating center. Subject visits to a clinical center will occur every four or six months. Data collected include demographic and clinical data, including the results of history and physical exams, laboratory and imaging data, repository specimens for special physiology studies, and genetic studies. Additionally, data regarding quality of life and compliance with assigned treatment will also be collected and assessed.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Placebo	Placebo Comparator	Placebo of spironolactone	Drug: Placebo
Spironolactone	Experimental	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.	Drug: Spironolactone

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Spironolactone	Drug	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Measure	Description	Time Frame
Composite Outcome of Cardiovascular Mortality, Aborted Cardiac Arrest, or Hospitalization for the Management of Heart Failure, Whichever Occurred First		Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

Measure	Description	Time Frame
Cardiovascular Mortality		Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
Aborted Cardiac Arrest	First incidence of aborted cardiac arrest

Eligibility Module

Eligibility Criteria

INCLUSION CRITERIA:

Heart failure as defined by at least one of symptom (paroxysmal nocturnal dyspnea; orthopnea; or dyspnea on mild or moderate exertion) at the time of screening and at least one sign (any rales post cough; jugular venous pressure(JVP) greater than or equal to 10cm of water(H2O); lower extremity edema; or chest x-ray demonstrating pleural effusion, pulmonary congestion, or cardiomegaly) within 12 months prior to study entry:
left ventricular ejection fraction greater than or equal to 45% (per local reading); the ejection fraction must have been obtained within 6 months prior to randomization and after any MI or other event that would affect ejection fraction
Controlled systolic blood pressure(BP), defined as a target systolic BP less than 140 mm Hg; participants with BP up to and including 160 mm Hg are eligible for enrollment if they are on three or more medications to control BP
Serum potassium less than 5.0 mmol/L prior to randomization
At least one hospital admission for which heart failure was a major component of the hospitalization some time within the 12 months prior to study entry OR brain natriuretic peptide (BNP) greater than or equal to 100pg/ml or N-terminal pro-BNP greater than or equal to 360pg/ml within the 60 days prior to study entry
Women of child-bearing potential must have a negative serum/urine pregnancy test within 72 hours prior to randomization, must not be lactating, and must agree to use an effective method of contraception during the entire course of study participation
Willing to comply with scheduled visits
Informed consent form signed by the subject prior to participation in the trial

EXCLUSION CRITERIA:

Severe systemic illness with an expected life expectancy of less than 3 years
Chronic pulmonary disease requiring home O2, oral steroid therapy, or hospitalization for exacerbation within 12 months of study entry, or significant chronic pulmonary disease in the opinion of the investigator
Known infiltrative or hypertrophic obstructive cardiomyopathy or known pericardial constriction
Primary hemodynamically significant uncorrected valvular heart disease, obstructive or regurgitant, or any valvular disease expected to lead to surgery during the trial
Atrial fibrillation with a resting heart rate greater than 90 bpm
MI in the past 90 days
Coronary artery bypass graft surgery in the past 90 days
Percutaneous coronary intervention in the past 30 days
Heart transplant recipient
Currently implanted left ventricular assist device
Stroke in past 90 days
Systolic BP (SBP) greater than 160 mm Hg
Known orthostatic hypotension
Gastrointestinal disorder that could interfere with study drug absorption
Use of any aldosterone antagonist or potassium sparing medication in the last 14 days or any known condition that would require the use of an aldosterone antagonist during study participation;
Known intolerance to aldosterone antagonists
Current lithium use
Current participation (including prior 30 days) in any other therapeutic trial
Any condition that, in the opinion of the investigator, may prevent the participant from adhering to the trial protocol
History of hyperkalemia (serum potassium greater than or equal to 5.5mmol/L) in the past 6 months or serum potassium greater than or equal to 5.0mmol/L within the past 2 weeks
Severe renal dysfunction, defined as an estimated glomerular filtration rate(GFR) less than 30ml/min. Participants with serum creatinine greater than or equal to 2.5mg/dl are also excluded even if their GFR is greater than or equal to 30ml/min
Known chronic hepatic disease, defined as aspartate aminotransferase(AST) and alanine aminotransferase(ALT) levels greater than 3.0 times the upper limit of normal as read at the local lab.

Name	Affiliation	Role
Sonja M. McKinlay, PhD	New England Research Institutes, Inc.	Principal Investigator

Facility	Status	City	State	ZIP	Country	Contacts
University of Alabama at Birmingham		Birmingham	Alabama	35294	United States
Cardiovascular Consultants, Ltd.

PubMed Identifier	Type	Citation	Retractions
22137068	Background	Desai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R, Clausell N, Diaz R, Fleg JL, Gordeev I, McKinlay S, O'Meara E, Shaburishvili T, Pitt B, Pfeffer MA. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J. 2011 Dec;162(6):966-972.e10. doi: 10.1016/j.ahj.2011.09.007. Epub 2011 Nov 8.
23258572

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	Placebo	Placebo of spironolactone
FG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age, Categorical

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
<=18 years	BG0000 BG0010 BG0020
Between 18 and 65 years

Age, Continuous

Median

Inter-Quartile Range

years

Title

Denominators

Categories

Title	Measurements
	BG00068.7(60.7 to 75.5) BG00168.7(61.0 to 76.4) BG002

Sex: Female, Male

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Female	BG000887 BG001888 BG002

Race (NIH/OMB)

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
American Indian or Alaska Native	BG0003 BG0016 BG002

Region of Enrollment

Number

participants

Title

Denominators

Categories

United States

Title	Measurements
	BG000579 BG001572 BG002

Eligibility Stratum

Eligible patients were assigned to one of two strata before randomization, according to whether they had at least one hospitalization within the previous 12 months in which management of heart failure was a major component of the care provided, or in absence of that criterion, an elevated brain natriuretic peptide (BNP) level within 60 days prior to randomization (a brain natriuretic peptide [BNP] level ≥100 pg per milliliter or an N-terminal pro-BNP [NTproBNP] level ≥360 pg per milliliter).

Number

participants

Title

Denominators

Categories

Hospitalization in previous year for heart failure

Title	Measurements
	BG0001232 BG001

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Composite Outcome of Cardiovascular Mortality, Aborted Cardiac Arrest, or Hospitalization for the Management of Heart Failure, Whichever Occurred First

All Participants who were randomized were included in the analysis. The analysis was Intention to Treat, meaning all participants were analyzed based on their initial treatment assignment and not on the treatment eventually received.

Posted

Number

Events per 100 person-years

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Units	Counts
Participants	OG0001723 OG0011722

Title

Denominators

Categories

Title	Measurements
	OG0006.6 OG0015.9

Group IDs	Group Description	Statistical Method	Statistical Comment	P-Value	P-Value Comment	Parameter Type	Parameter Value	Dispersion Type	Dispersion Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	CI Lower Limit Comment	CI Upper Limit Comment	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type	Non-Inferiority Comment	Other Analysis Description
OG000 OG001	Composite endpoint was compared by trial arm using logrank test of time to first event from time of randomization. Time to event was the time at which the first observed event component of the composite endpoint was observed. This endpoint was adjudicated by the TOPCAT clinical endpoints committee. There were 320 subjects in the Spironolactone group and 351 subjects in Placebo group with a confirmed event. Subjects who did not experience this endpoint were censored at time of last contact.	Log Rank	Two-sided log rand test (0.05 Type 1 error)	0.14	No covariate adjustment	Hazard Ratio (HR)	0.89			2-Sided	95	0.77	1.04			Spironolactone compared to Placebo

Secondary

Cardiovascular Mortality

Posted

Number

Events per 100 person-years

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Units	Counts
Participants	OG000

Secondary

Aborted Cardiac Arrest

First incidence of aborted cardiac arrest

Posted

Number

Events per 100 person-years

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Units	Counts
Participants	OG000

Secondary

Hospitalization for the Management of Heart Failure

First incidence of a hospitalization for the management of heart failure

Posted

Number

Events per 100 person-years

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Units	Counts
Participants	OG000

Secondary

All-cause Mortality

Posted

Number

Events per 100 person-years

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Units	Counts
Participants	OG000

Secondary

Composite Outcome of Cardiovascular Mortality or Cardiovascular-related Hospitalization (i.e., Hospitalization for Myocardial Infarction(MI), Stroke, or the Management of Heart Failure), Whichever Occurred First

Posted

Number

Events per 100 person-years

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Units	Counts
Participants

Secondary

Cardiovascular-related Hospitalization

Hospitalization for MI, stroke or the management of heart failure, whichever occurred first

Posted

Number

Events per 100 person-years

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Units	Counts
Participants

Secondary

Total Hospitalizations (Including Repeat Hospitalizations) for the Management of Heart Failure

Posted

Number

Events per 100 person-years

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Units	Counts
Participants	OG000

Secondary

Composite Outcome of Sudden Death or Aborted Cardiac Arrest, Whichever Occurred First

Posted

Number

Events per 100 person-years

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Units	Counts
Participants	OG000

Secondary

New Onset Diabetes Mellitus, Among Subjects Without a History of Diabetes Mellitus at Baseline.

First incidence of new onset diabetes mellitus among subjects without a history of diabetes mellitus at baseline.

All Participants who were randomized and did not have a history of diabetes mellitus at baseline were included in the analysis. The analysis was Intention to Treat, meaning all participants were analyzed based on their initial treatment assignment and not on the treatment eventually received.

Posted

Number

Events per 100 person-years

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Units	Counts
Participants

Secondary

Development of Atrial Fibrillation, Among Subjects Without a History of Atrial Fibrillation at Baseline.

First incidence of atrial fibrillation among subjects without a history of atrial fibrillation at baseline

All Participants who were randomized and did not have a history of atrial fibrillation at baseline were included in the analysis. The analysis was Intention to Treat, meaning all participants were analyzed based on their initial treatment assignment and not on the treatment eventually received.

Posted

Number

Events per 100 person-years

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Units	Counts
Participants

Secondary

Myocardial Infarction

First incidence of myocardial infarction

Posted

Number

Events per 100 person-years

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Units	Counts
Participants	OG000

Secondary

Stroke

First incidence of stroke

Posted

Number

Events per 100 person-years

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Units	Counts
Participants	OG000

Secondary

Deterioration of Renal Function

First incidence of a deterioration of renal function. The TOPCAT protocol defines deterioration of renal function as occurring if a subject has a serum creatinine value which is at least double the baseline value for that subject, and is also above the upper limit of normal (assumed to be 1.0 mg/dL for females and 1.2 mg/dL for males.)

Posted

Number

Events per 100 person-years

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Units	Counts

Secondary

Composite Outcome of Sudden Death, Aborted Cardiac Arrest, or Hospitalization for the Management of Ventricular Tachycardia, Whichever Occurred First

Posted

Number

Events per 100 person-years

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Units	Counts
Participants	OG000

Secondary

Quality of Life, as Measured by the Kansas City Cardiomyopathy Questionnaire.

Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.

The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. The KCCQ was administered at the following study visits: baseline, month 4, month 12 and annually thereafter.

Posted

Least Squares Mean

Standard Error

units on a scale

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Secondary

Quality of Life, as Measured by the EuroQOL Visual Analog Scale.

The EuroQOL visual analog scale (EQ5D) is a single-item, self-administered instrument that quantifies current health status. Scores can range from 0-100, in which higher scores reflect better health status. The EQ5D was administered at the following study visits: baseline, month 4, month 12 and annually thereafter.

Posted

Least Squares Mean

Standard Error

units on a scale

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Secondary

Quality of Life, as Measured by McMaster Overall Treatment Evaluation Questionnaire.

Average post-baseline quality of life, taking into consideration baseline quality of life and treatment group.

The McMaster Overall Treatment Evaluation questionnaire is a self-administered 3-item instrument that measures a patient's perception of change in their health-related quality of life since the start of therapy. The questionnaire consists of a single question - "Since treatment started, has there been any change in your activity limitation, symptoms and/or feelings related to your heart condition?" Scores can range from -7 to +7, and higher scores reflect better health status. The questionnaire was administered at the following study visits: month 4 and month 12. Valid translations of this questionnaire were only available for subjects enrolled in the United States, Canada and Argentina.

All Participants from United States, Canada and Argentina who were randomized were included in the analysis. The analysis was Intention to Treat, meaning all participants were analyzed based on their initial treatment assignment and not on the treatment eventually received.

Posted

Least Squares Mean

Standard Error

units on a scale

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Secondary

Depression Symptoms, as Measured by Patient Health Questionnaire.

Average post-baseline depression, taking into consideration baseline depression, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.

The Patient Health Questionnaire (PHQ) is a 10-item, self-administered instrument for screening, diagnosing, monitoring and measuring the severity of depression. Scores can range from 0-27, in which lower scores reflect better mental health status. The PH-Q was administered at the following study visits: baseline, month 12 and annually thereafter. Valid translations of this questionnaire were only available for subjects enrolled in the United States and Canada.

All Participants from the United States and Canada who were randomized were included in the analysis. The analysis was Intention to Treat, meaning all participants were analyzed based on their initial treatment assignment and not on the treatment eventually received.

Posted

Least Squares Mean

Standard Error

units on a scale

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Secondary

Hospitalization for Any Reason

First incidence of a hospitalization for any reason

Posted

Number

Events per 100 person-years

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Units	Counts
Participants	OG000

Secondary

Potassium

Average post-baseline Potassium, taking into consideration baseline Potassium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.

Posted

Least Squares Mean

Standard Error

mEq/L

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Units	Counts
Participants

Secondary

Serum Creatinine

Average post-baseline serum creatinine, taking into consideration baseline serum creatinine, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.

Posted

Least Squares Mean

Standard Error

mg/dL

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Units	Counts
Participants

Secondary

Sodium

Average post-baseline Sodium, taking into consideration baseline Sodium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.

Posted

Least Squares Mean

Standard Error

mEq/L

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Units	Counts
Participants

Secondary

Chloride

Average post-baseline Chloride, taking into consideration baseline Chloride, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.

Posted

Least Squares Mean

Standard Error

mEq/L

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Units	Counts
Participants

Secondary

Estimated Glomerular Filtration Rate (GFR)

Average post-baseline GFR, taking into consideration baseline GFR, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.

Posted

Least Squares Mean

Standard Error

mL/min/1.73m2

Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

ID	Title	Description
OG000	Placebo	Placebo of spironolactone
OG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Units	Counts
Participants

Serious Adverse Events

Term	Organ System	Assessment Type	Statistical Information
ABDOMINAL AORTIC ANEURYSM	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ABDOMINAL AORTIC ANEURYSM	Vascular disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
ABDOMINAL PAIN	Gastrointestinal disorders	Systematic Assessment	EG0007 events7 affected1,723 at risk EG00110 events10 affected1,722 at risk
ABDOMINAL PAIN	Hepatobiliary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ABDOMINAL PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ABDOMINAL PAIN	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ABDOMINAL VISCUS PERFORATION	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ABNORMAL ELECTROLYTE	Metabolism and nutrition disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ABNORMAL LAB VALUE	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ABNORMAL VAGINAL BLEEDING	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ABNORMAL VAGINAL BLEEDING	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ABSCESS	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ABSCESS	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ABSCESS	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ACID REFLUX	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ACTINIC KERATOSIS	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ACUTE CORONARY SYNDROME	Cardiac disorders	Systematic Assessment	EG0009 events9 affected1,723 at risk EG00111 events11 affected1,722 at risk
ACUTE MENIERE'S DISEASE	Ear and labyrinth disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ACUTE RESPIRATORY DISTRESS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
ADRENAL INSUFFIENCY	Endocrine disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ALCOHOL WITHDRAWAL	General disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ALLERGY	Immune system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ALTERED MENTAL STATUS	Nervous system disorders	Systematic Assessment	EG0009 events9 affected1,723 at risk EG0018 events8 affected1,722 at risk
ALVEOLITIS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ALZHEIMER'S DISEASE	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
AMYLOIDOSIS	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
AMYLOIDOSIS	Immune system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
AMYOTROPHIC LATERAL SCLEROSIS	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ANAL CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ANEMIA	Blood and lymphatic system disorders	Systematic Assessment	EG00026 events23 affected1,723 at risk EG00118 events15 affected1,722 at risk
ANEMIA	Gastrointestinal disorders	Systematic Assessment	EG0003 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
ANEURYSM	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ANEURYSM	Vascular disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0010 events0 affected1,722 at risk
ANGIOEDEMA	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ANGIOGRAPHY	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ANGIOPLASTY	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
ANXIETY	Nervous system disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
AORTIC ANEURYSM	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
AORTIC ANEURYSM	Vascular disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
AORTIC REGURGITATION	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
AORTIC STENOSIS	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0015 events5 affected1,722 at risk
APPENDECTOMY	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
APPENDICEAL ABCESS	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
APPENDICITIS	Gastrointestinal disorders	Systematic Assessment	EG0005 events5 affected1,723 at risk EG0011 events1 affected1,722 at risk
ARM INJURY	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
ARM INJURY	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ARM INJURY	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ARRHYTHMIA	Cardiac disorders	Systematic Assessment	EG0006 events6 affected1,723 at risk EG0016 events6 affected1,722 at risk
ARTERIAL OCCLUSIVE DISEASE	Vascular disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
ARTERIAL STENOSIS	Cardiac disorders	Systematic Assessment	EG0002 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
ARTERIAL STENOSIS	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ARTERIAL THROMBOSIS	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ARTERIAL THROMBOSIS	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ARTHRALGIA	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ARTHRITIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0013 events3 affected1,722 at risk
ARTHROPLASTY	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ASCITES	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ASCITES	General disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ASCITES	Hepatobiliary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ASTHMA	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0007 events5 affected1,723 at risk EG0016 events5 affected1,722 at risk
ATAXIA	Nervous system disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
ATHEROSCLEROSIS	Cardiac disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0011 events1 affected1,722 at risk
ATHEROSCLEROSIS	Vascular disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
ATRIAL FIBRILLATION	Cardiac disorders	Systematic Assessment	EG00069 events58 affected1,723 at risk EG00192 events73 affected1,722 at risk
ATRIAL FIBRILLATION	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ATRIAL FIBRILLATION	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ATRIAL FLUTTER	Cardiac disorders	Systematic Assessment	EG00010 events6 affected1,723 at risk EG00110 events8 affected1,722 at risk
AV BLOCK	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0013 events3 affected1,722 at risk
AV REPLACEMENT	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
AV STENOSIS	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
AZOTEMIA	Blood and lymphatic system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
BACK INJURY	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
BACK PAIN	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
BACK PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG00112 events10 affected1,722 at risk
BACTERIAL INFECTION	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
BARIATRIC SURGERY	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
BELLS PALSY	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
BI BLEED	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
BILE DUCT CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
BILIARY COLIC	Hepatobiliary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
BINODAL DISEASE	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
BIPOLAR DISORDER	Psychiatric disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
BLADDER CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
BLADDER OBSTRUCTION	Renal and urinary disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
BLEEDING IN EYE	Eye disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0013 events1 affected1,722 at risk
BLISTERS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
BLOOD IN STOOL	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
BLURRED VISION	Eye disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
BODY PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
BOWEL CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0002 events1 affected1,723 at risk EG0016 events5 affected1,722 at risk
BOWEL OBSTRUCTION	Gastrointestinal disorders	Systematic Assessment	EG0007 events5 affected1,723 at risk EG0017 events7 affected1,722 at risk
BOWEL PERFORATION	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
BRADYCARDIA	Cardiac disorders	Systematic Assessment	EG00011 events10 affected1,723 at risk EG0019 events9 affected1,722 at risk
BRAIN CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
BRAIN CANCER	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
BRAIN HEMORRHAGE	Blood and lymphatic system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
BRAIN HEMORRHAGE	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
BRAIN HEMORRHAGE	Nervous system disorders	Systematic Assessment	EG0004 events3 affected1,723 at risk EG0011 events1 affected1,722 at risk
BRAIN TUMOR	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
BREAST CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0006 events6 affected1,723 at risk EG0014 events3 affected1,722 at risk
BREAST REDUCTION	Surgical and medical procedures	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
BREAST TUMOR	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
BRONCHIECTASIS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
BRONCHITIS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG00015 events15 affected1,723 at risk EG00112 events11 affected1,722 at risk
BRUISE	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
BUTTOCK PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
C-DIFF INFECTION	Infections and infestations	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0012 events2 affected1,722 at risk
CABG	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
CABG	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
CARDIAC ARREST	Cardiac disorders	Systematic Assessment	EG00012 events12 affected1,723 at risk EG00110 events10 affected1,722 at risk
CARDIAC ARRYTHMIA	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
CARDIAC CATHETERIZATION	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
CARDIAC CIRRHOSIS	Hepatobiliary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
CARDIAC TAMPONADE	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
CARDIO RENAL SYNDROME	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
CARDIOGENIC SHOCK	Cardiac disorders	Systematic Assessment	EG0005 events4 affected1,723 at risk EG0013 events3 affected1,722 at risk
CARDIOMYOPATHY	Cardiac disorders	Systematic Assessment	EG0004 events3 affected1,723 at risk EG0012 events2 affected1,722 at risk
CARDIOPULMONARY ARREST	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0015 events5 affected1,722 at risk
CARDIOSCLEROSIS	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
CAROTID STENOSIS	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
CAROTID STENOSIS	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
CAROTID STENT	Surgical and medical procedures	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
CATARACTS	Eye disorders	Systematic Assessment	EG0007 events5 affected1,723 at risk EG0017 events5 affected1,722 at risk
CELLULITIS	Infections and infestations	Systematic Assessment	EG00014 events14 affected1,723 at risk EG00114 events13 affected1,722 at risk
CELLULITIS	Skin and subcutaneous tissue disorders	Systematic Assessment	EG00025 events21 affected1,723 at risk EG00117 events14 affected1,722 at risk
CENTRAL CHORIORETINAL DYSTROPHY	Eye disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
CHEST PAIN	Cardiac disorders	Systematic Assessment	EG000186 events144 affected1,723 at risk EG001203 events143 affected1,722 at risk
CHEST PAIN	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
CHEST PAIN	Investigations	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
CHEST PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0005 events5 affected1,723 at risk EG0018 events6 affected1,722 at risk
CHEST PAIN	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
CHOLANGIOCARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events1 affected1,722 at risk
CHOLANGITIS	Hepatobiliary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
CHOLE	Hepatobiliary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
CHOLECYSTECTOMY	Hepatobiliary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
CHOLECYSTECTOMY	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
CHOLECYSTECTOMY	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
CHOLECYSTITIS	Hepatobiliary disorders	Systematic Assessment	EG00011 events10 affected1,723 at risk EG0017 events7 affected1,722 at risk
CHOLECYSTITIS	Renal and urinary disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
CHOLESTASIS	Hepatobiliary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
CHOLESTATIC SYNDROME	Hepatobiliary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
CHOPPED WOUND OF LEFT HAND	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
CHORIORRETINOPATHY	Eye disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
CHRONIC OBSTRUCTIVE PULMONARY DISEASE	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0013 events1 affected1,722 at risk
CHRONIC OBSTRUCTIVE PULMONARY DISEASE	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
CHRONIC OBSTRUCTIVE PULMONARY DISEASE	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG00024 events21 affected1,723 at risk EG00132 events23 affected1,722 at risk
CIRRHOSIS	Hepatobiliary disorders	Systematic Assessment	EG0002 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
COLD EXTREMITIES	Vascular disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
COLITIS	Gastrointestinal disorders	Systematic Assessment	EG0006 events6 affected1,723 at risk EG0013 events3 affected1,722 at risk
COLON CANCER	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
COLON CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0005 events4 affected1,723 at risk EG0013 events3 affected1,722 at risk
CONFUSION	Nervous system disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0011 events1 affected1,722 at risk
CONGESTIVE HEART FAILURE	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0013 events2 affected1,722 at risk
CONSTIPATION	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
CORONAROGRAPHY	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
CORONARY ANGIOGRAPHY	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
CORONARY ARTERY BYPASS GRAFT	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
CORONARY ARTERY DISEASE	Cardiac disorders	Systematic Assessment	EG00018 events17 affected1,723 at risk EG00115 events15 affected1,722 at risk
CORONARY ARTERY STENT	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
CORONARY REVASCULARIZATION	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
CORONARY VASOSPASM	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
CORRECTION THERAPY	Surgical and medical procedures	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
COUGH	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
COUMADIN TOXICITY	Blood and lymphatic system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events1 affected1,722 at risk
CROHNS DISEASE	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
DEATH	Cardiac disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0014 events4 affected1,722 at risk
DEATH	General disorders	Systematic Assessment	EG00084 events83 affected1,723 at risk EG00171 events71 affected1,722 at risk
DEATH	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
DEATH	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
DECREASED APPETITE	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
DEEP VEIN THROMBOSIS	Vascular disorders	Systematic Assessment	EG0007 events6 affected1,723 at risk EG0015 events4 affected1,722 at risk
DEHYDRATION	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
DEHYDRATION	General disorders	Systematic Assessment	EG0008 events8 affected1,723 at risk EG0017 events7 affected1,722 at risk
DEHYDRATION	Metabolism and nutrition disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
DEMENTIA	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
DENATURED ALCOHOL POISONING	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
DENTAL ABSCESS	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
DEPRESSION	Psychiatric disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0015 events3 affected1,722 at risk
DESTABILIZATION OF BLOOD PRESSURE	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
DEVICE CHANGE	Cardiac disorders	Systematic Assessment	EG0006 events6 affected1,723 at risk EG0015 events5 affected1,722 at risk
DEVICE IMPLANT	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
DEVICE MALFUNCTION	Cardiac disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0010 events0 affected1,722 at risk
DIABETES	Endocrine disorders	Systematic Assessment	EG0006 events6 affected1,723 at risk EG00117 events14 affected1,722 at risk
DIARRHEA	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
DIARRHEA	Gastrointestinal disorders	Systematic Assessment	EG0008 events7 affected1,723 at risk EG0016 events5 affected1,722 at risk
DILATED ESOPHAGUS	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
DISCITIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0013 events1 affected1,722 at risk
DISSEMINATED INTRAVASCULAR COAGULATION	Blood and lymphatic system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
DIVERTICULITIS	Gastrointestinal disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0012 events2 affected1,722 at risk
DIVERTICULOSIS	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0013 events2 affected1,722 at risk
DIZZINESS	General disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0015 events5 affected1,722 at risk
DIZZINESS	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0013 events3 affected1,722 at risk
DORSOPATHY	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
DRUG OVERDOSE	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
DRUG TOXOCITY	Blood and lymphatic system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
DRY EYES	Eye disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
DYSARTHRIA	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
DYSPHAGIA	Gastrointestinal disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0010 events0 affected1,722 at risk
DYSPHAGIA	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
DYSPNEA	Cardiac disorders	Systematic Assessment	EG00012 events11 affected1,723 at risk EG00113 events11 affected1,722 at risk
DYSPNEA	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
DYSPNEA	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0013 events3 affected1,722 at risk
EDEMA	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
EDEMA	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
ELECTIVE BAND PROCEDURE	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ELECTROLYTE IMBALANCE	General disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ELECTROLYTE IMBALANCE	Metabolism and nutrition disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ELEVATED CARDIAC ENZYMES	Cardiac disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0012 events2 affected1,722 at risk
ELEVATED CREATININE	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0015 events5 affected1,722 at risk
ELEVATED INR	Blood and lymphatic system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
ELEVATED LIVER ENZYMES	Hepatobiliary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ELEVATED PT	Blood and lymphatic system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
EMBOLECTOMY	Surgical and medical procedures	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ENCEPHALITIS	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ENCEPHALOPATHY	Hepatobiliary disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0013 events1 affected1,722 at risk
ENCEPHALOPATHY	Nervous system disorders	Systematic Assessment	EG0006 events5 affected1,723 at risk EG0018 events8 affected1,722 at risk
ENDARTERECTOMY	Surgical and medical procedures	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
ENDOCARDITIS	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0013 events3 affected1,722 at risk
ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ENTERITIS	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ENTEROCOLITIS	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
EPIDIDYMITIS	Reproductive system and breast disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0014 events3 affected1,722 at risk
EPIGASTRIC PAIN	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
EPISTAXIS	Blood and lymphatic system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
EPISTAXIS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
EPISTAXIS	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0013 events2 affected1,722 at risk
EQUIPMENT MALFUNCTION	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ERECTILE DYSFUNCTION	Reproductive system and breast disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
EROSION OF PACEMAKER POCKET	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
EROSION OF THE VAGINAL EPITHELIUM	Reproductive system and breast disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ESOPHAGEAL CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
ESOPHAGITIS	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
EXACERBATION OF THE CHRONIC CALCULOUS CHOLECYSTITIS	Hepatobiliary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
EXTRASYSTOLE	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
EYE LESION	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
EYE SURGERY	Eye disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events1 affected1,722 at risk
FAILURE TO THRIVE	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
FAILURE TO THRIVE	General disorders	Systematic Assessment	EG0006 events6 affected1,723 at risk EG0010 events0 affected1,722 at risk
FALL	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
FALL	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0017 events7 affected1,722 at risk
FALL	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
FASCIOTOMY	Surgical and medical procedures	Systematic Assessment	EG0002 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
FATIGUE	General disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
FECAL IMPACTION	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
FEMORAL EMBOLUS	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
FEVER	General disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
FISTULA	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
FISTULA	Injury, poisoning and procedural complications	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
FOOT INJURY	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
FOOT PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
FOOT ULCER	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
FRACTURE	Injury, poisoning and procedural complications	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0011 events1 affected1,722 at risk
FRACTURE	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG00041 events39 affected1,723 at risk EG00134 events31 affected1,722 at risk
GALLSTONES	Hepatobiliary disorders	Systematic Assessment	EG00011 events10 affected1,723 at risk EG0016 events6 affected1,722 at risk
GANGRENE	Infections and infestations	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
GANGRENE	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0014 events4 affected1,722 at risk
GASTRECTOMY	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
GASTRIC BYPASS SURGERY	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
GASTRIC BYPASS SURGERY	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
GASTRIC REFLUX	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
GASTRITIS	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0013 events3 affected1,722 at risk
GASTROENTERITIS	Gastrointestinal disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0017 events7 affected1,722 at risk
GASTROPARESIS	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
GATRITIS	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
GENERAL HEALTH DECLINE	General disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0013 events3 affected1,722 at risk
GERD	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
GI BLEED	Gastrointestinal disorders	Systematic Assessment	EG00030 events22 affected1,723 at risk EG00126 events25 affected1,722 at risk
GI DISTRESS	Gastrointestinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
GOUT	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG00011 events6 affected1,723 at risk EG0016 events6 affected1,722 at risk
GROIN PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
GUILLIAN BARRE SYNDROME	Immune system disorders	Systematic Assessment	EG0002 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
GYNECOMASTIA	Endocrine disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
GYNECOMASTIA	Reproductive system and breast disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events1 affected1,722 at risk
HAND PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HEAD INJURY	Injury, poisoning and procedural complications	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0010 events0 affected1,722 at risk
HEAD INJURY	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
HEADACHE	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0015 events5 affected1,722 at risk
HEARING LOSS	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
HEART	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
HEART BLOCK	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HEART FAILURE	Cardiac disorders	Systematic Assessment	EG000532 events294 affected1,723 at risk EG001465 events256 affected1,722 at risk
HEART FAILURE	Congenital, familial and genetic disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HEART FAILURE	Endocrine disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
HEART FAILURE	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
HEART FAILURE	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
HEART FAILURE	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
HEART FAILURE	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0012 events2 affected1,722 at risk
HEART SURGERY	Surgical and medical procedures	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HEARTBURN	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
HEAT	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
HEEL PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HEMATOCHEZIA	Gastrointestinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
HEMATOMA	Blood and lymphatic system disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0010 events0 affected1,722 at risk
HEMATOMA	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HEMATOMA	Nervous system disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0011 events1 affected1,722 at risk
HEMATOMA	Vascular disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
HEMATURIA	Renal and urinary disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0015 events5 affected1,722 at risk
HEMOPTYSIS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
HEMORRHAGE	Gastrointestinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0013 events3 affected1,722 at risk
HEMORRHAGE	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HEMORRHAGE	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HEMORRHAGE	Vascular disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
HEMORRHOIDS	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HEPARIN BRIDGING	Surgical and medical procedures	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HEPATIC ENCEPHALOPATHY	Hepatobiliary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HEPATOMEGALY	Hepatobiliary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
HERNIA	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HERNIA	Gastrointestinal disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0011 events1 affected1,722 at risk
HERNIA	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HERNIA	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG00110 events8 affected1,722 at risk
HERNIA	Surgical and medical procedures	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HERNIATED DISC	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events1 affected1,722 at risk
HIATAL HERNIA	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HIP PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HIP REPLACEMENT	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
HIP REPLACEMENT	Surgical and medical procedures	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HOSPITALIZATION	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
HYDRONEPHROSIS	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
HYPERCALCEMIA	General disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
HYPERCAPNIA	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HYPEREMIA	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HYPERGLYCEMIA	Endocrine disorders	Systematic Assessment	EG0004 events2 affected1,723 at risk EG00110 events9 affected1,722 at risk
HYPERKALEMIA	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
HYPERKALEMIA	Renal and urinary disorders	Systematic Assessment	EG0005 events5 affected1,723 at risk EG00121 events20 affected1,722 at risk
HYPERNATREMIA	Metabolism and nutrition disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HYPERPLASIA	Reproductive system and breast disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
HYPERTENSION	Cardiac disorders	Systematic Assessment	EG00024 events21 affected1,723 at risk EG00132 events27 affected1,722 at risk
HYPERTENSION	General disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
HYPERTENSION	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HYPERTHYROIDISM	Endocrine disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
HYPERVOLEMIA	Cardiac disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0011 events1 affected1,722 at risk
HYPERVOLEMIA	General disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
HYPOGLYCEMIA	Endocrine disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0018 events7 affected1,722 at risk
HYPOKALEMIA	Renal and urinary disorders	Systematic Assessment	EG0005 events4 affected1,723 at risk EG0010 events0 affected1,722 at risk
HYPONATREMIA	Endocrine disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
HYPONATREMIA	General disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
HYPONATREMIA	Metabolism and nutrition disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
HYPONATREMIA	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
HYPOTENSION	Cardiac disorders	Systematic Assessment	EG00018 events18 affected1,723 at risk EG00118 events17 affected1,722 at risk
HYPOTENSION	Endocrine disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HYPOVENTILATION	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HYPOVOLEMIA	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
HYPOVOLEMIA	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
HYPOXEMIA	Blood and lymphatic system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
HYPOXIA	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0012 events2 affected1,722 at risk
HYSTERECTOMY	Reproductive system and breast disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ICD IMPLANTATION	Surgical and medical procedures	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
ICD MALFUNCTION	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
ILEITIS	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
ILEUS	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
IN-STENT RESTENOSIS	Cardiac disorders	Systematic Assessment	EG0002 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
INCREASE THIGH MASS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
INCREASING NITRONGENATED SCORIAS	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
INFECTION	Infections and infestations	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0014 events3 affected1,722 at risk
INFECTION	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
INFLUENZA	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
INTESTINAL CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
INTESTINAL PERFORATION	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
INTRACRANIAL BLEED	Blood and lymphatic system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
JAUNDICE	Hepatobiliary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
KIDNEY DISEASE	Cardiac disorders	Systematic Assessment	EG0006 events5 affected1,723 at risk EG0014 events4 affected1,722 at risk
KIDNEY DISEASE	General disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
KIDNEY DISEASE	Metabolism and nutrition disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
KIDNEY DISEASE	Renal and urinary disorders	Systematic Assessment	EG00068 events51 affected1,723 at risk EG00179 events63 affected1,722 at risk
KIDNEY DISEASE	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
KIDNEY FAILURE	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
KIDNEY INFECTION	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
KIDNEY STONE	Renal and urinary disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0013 events3 affected1,722 at risk
KNEE AMPUTATION	Vascular disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
KNEE ARTHROPLASTY	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
KNEE INJURY	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
KNEE PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0012 events2 affected1,722 at risk
KNEE SURGERY	Surgical and medical procedures	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0013 events3 affected1,722 at risk
LABYRINTHITIS	Ear and labyrinth disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
LARYNGEAL CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
LARYNGEAL EDEMA	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
LEG AMPUTATION	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
LEG CLAUDICATION	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
LEG INJURY	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
LEG PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
LEG ULCERS	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
LESION	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
LEUKEMIA	Blood and lymphatic system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
LEUKEMIA	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
LEUKEMIA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
LEUKOCYTOSIS	Blood and lymphatic system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
LIMB ISCHEMIA	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
LIVER CANCER	Hepatobiliary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
LIVER CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0012 events1 affected1,722 at risk
LIVER LACERATION	Hepatobiliary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
LOWER EXTREMITY EDEMA	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
LOWER EXTREMITY ISCHEMIA	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
LUNG CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0004 events3 affected1,723 at risk EG0019 events9 affected1,722 at risk
LUNG CONTUSION	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
LYMPHANGITIS	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
LYMPHOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG00011 events4 affected1,723 at risk EG0010 events0 affected1,722 at risk
MALLORY-WEISS SYNDROME	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
MALNUTRITION	Metabolism and nutrition disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
MEDICAL EXAM	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
MEDICAL EXAM	Investigations	Systematic Assessment	EG00033 events23 affected1,723 at risk EG00134 events22 affected1,722 at risk
MEDICATION ADJUSTMENT	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
MEGACOLON	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
MENINGITIS	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
MESENTERIC ISCHEMIA	Gastrointestinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
METABOLIC ACIDOSIS	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
MITRAL REGURGITATION	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events1 affected1,722 at risk
MITRAL VALVE REPLACEMENT	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
MOTOR VEHICLE ACCIDENT	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
MRSA INFECTION	Infections and infestations	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0011 events1 affected1,722 at risk
MULTIPLE INFIRMITIES OF AGING	General disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
MULTIPLE ORGAN FAILURE	General disorders	Systematic Assessment	EG0004 events3 affected1,723 at risk EG0013 events3 affected1,722 at risk
MYASTHENIA GRAVIS	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
MYELOPATHY	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
MYOCARDIAL INFARCTION	Cardiac disorders	Systematic Assessment	EG00079 events67 affected1,723 at risk EG00183 events66 affected1,722 at risk
MYOCARDIAL INFARCTION	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
MYOCARDIAL INFECTION	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
MYOCLONIA	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
MYOMA	Reproductive system and breast disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
MYOPATHY	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
NAUSEA	Gastrointestinal disorders	Systematic Assessment	EG0005 events5 affected1,723 at risk EG0011 events1 affected1,722 at risk
NECK CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
NEPHRECTOMY	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
NEURONITIS	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
NEUROPATHY	Endocrine disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events1 affected1,722 at risk
NEUROPATHY	Nervous system disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0010 events0 affected1,722 at risk
NON-CALCULOUS CHOLECYSTITIS	Hepatobiliary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
OBSTRUCTIVE UROPATHY	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
OBTURATIVE SUPPURATIVE GANGRENOUSE CALCULOUS CHOLECYSTITIS	Hepatobiliary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
OEDEMA	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
OPISTHORCHOSIS	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
OPISTHORCHOSIS	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
OPTIC ATROPHY	Eye disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events1 affected1,722 at risk
ORTHOPNEA	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
OSTEOARTHRITIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0007 events7 affected1,723 at risk EG00112 events10 affected1,722 at risk
OSTEOCHONDROSIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0013 events3 affected1,722 at risk
OSTEOMYELITIS	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
OSTEOMYELITIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0015 events5 affected1,722 at risk
OVERACTIVE BLADDER	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
PACEMAKER IMPLANT	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
PALPITATIONS	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
PANCREATIC CANCER	Endocrine disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
PANCREATIC CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0014 events4 affected1,722 at risk
PANCREATIC MASS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
PANCREATITIS	Endocrine disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0013 events2 affected1,722 at risk
PANCREATITIS	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
PANCREATITIS	Hepatobiliary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0019 events7 affected1,722 at risk
PANCYTOPENIA	Blood and lymphatic system disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
PARASTHESIA	Nervous system disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
PARKINSON'S DISEASE	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
PAROTID GLAND CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
PATHOLOGY OF ENDOMETRIUM	Reproductive system and breast disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
PENILE BLEEDING	Reproductive system and breast disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
PERCUTANEOUS CORONARY INTERVENTION	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
PERICARDITIS	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
PERIPHERAL ARTERIAL DISEASE	Vascular disorders	Systematic Assessment	EG00011 events6 affected1,723 at risk EG0011 events1 affected1,722 at risk
PERIPHERAL VASCULAR DISEASE	Vascular disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
PERITONITIS	Gastrointestinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
PERITONITIS	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
PHLEBOTHROMBOSIS	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
PLEURAL EFFUSION	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
PLEURAL EFFUSION	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0005 events5 affected1,723 at risk EG00112 events9 affected1,722 at risk
PLEURISY	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
PNEUMONIA	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
PNEUMONIA	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
PNEUMONIA	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG00083 events75 affected1,723 at risk EG00187 events76 affected1,722 at risk
POLYMYALGIA	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
POLYP REMOVAL	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
POLYPS	Gastrointestinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
POLYPS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0005 events4 affected1,723 at risk EG0010 events0 affected1,722 at risk
POLYPS	Reproductive system and breast disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
POST-MENOPAUSAL BLEEDING	Reproductive system and breast disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
PRE-CANCEROUS TUMOR SURGERY, LEFT TEMPORAL LEVEL.	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
PREVENTIVE TREATMENT	Surgical and medical procedures	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
PROCTITIS	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
PROPHYLACTIC THERAPY	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
PROSTATE CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0013 events3 affected1,722 at risk
PROSTATE CANCER	Reproductive system and breast disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
PROSTATE SURGERY	Surgical and medical procedures	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
PROSTATIC HYPERPLASIA	Reproductive system and breast disorders	Systematic Assessment	EG0005 events5 affected1,723 at risk EG0012 events2 affected1,722 at risk
PROSTATITIS	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
PROSTATITIS	Reproductive system and breast disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
PSYCHOSIS	Psychiatric disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
PULMONARY CONGESTION	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
PULMONARY EDEMA	Cardiac disorders	Systematic Assessment	EG0004 events3 affected1,723 at risk EG0015 events3 affected1,722 at risk
PULMONARY EDEMA	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG00012 events8 affected1,723 at risk EG00111 events10 affected1,722 at risk
PULMONARY EMBOLISM	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
PULMONARY EMBOLISM	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0009 events9 affected1,723 at risk EG0018 events8 affected1,722 at risk
PULMONARY EMBOLUS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
PULMONARY FIBROSIS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
PULMONARY OVERLOAD	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0004 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
PURPURA	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events1 affected1,722 at risk
PYELOCYSTITIS	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
PYELONEPHRITIS	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
PYELONEPHRITIS	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
RADIATION	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
RADIOFREQUENCY ABLATION	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
RADIOFREQUENCY ABLATION	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
RECTAL CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
RECTAL PROLAPSE SURGERY	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
RECTOVESICAL FISTULA	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
RECTUS HEMATOMA	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
REMOVAL OF ADHESIONS	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
RENAL CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
RENAL FAILURE	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
RENAL MASS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
RESECTION OF CUBITAL	Surgical and medical procedures	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
RESPIRATORY ARREST	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
RESPIRATORY CONGESTION	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
RESPIRATORY DISTRESS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0011 events1 affected1,722 at risk
RESPIRATORY FAILURE	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
RESPIRATORY FAILURE	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG00013 events11 affected1,723 at risk EG00110 events10 affected1,722 at risk
RESPIRATORY INSUFFICIENCY	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
RESPIRATORY INSUFFICIENCY	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0010 events0 affected1,722 at risk
RESPIRATORY TRACT INFECTION	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
RETINAL ANGIOPATHY	Eye disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
RETINAL DETACHMENT	Eye disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
RETINOPATHY	Eye disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
RHABDOMYOLYSIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0010 events0 affected1,722 at risk
RUPTURED ESOPHAGUS	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
SALMONELLOSIS	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
SCIATICA	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
SCLERODERMA	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
SCLERODERMA	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
SCLERODERMA	Vascular disorders	Systematic Assessment	EG0002 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
SCLEROTIC METASTASIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
SECONDARY TO ANTIARRHYTHMIC MEDICATION	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
SEIZURE	Nervous system disorders	Systematic Assessment	EG0005 events4 affected1,723 at risk EG0011 events1 affected1,722 at risk
SEPSIS	General disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
SEPSIS	Infections and infestations	Systematic Assessment	EG00015 events15 affected1,723 at risk EG00116 events16 affected1,722 at risk
SEPSIS	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
SEPTIC SHOCK	Infections and infestations	Systematic Assessment	EG0005 events5 affected1,723 at risk EG0013 events3 affected1,722 at risk
SEPTIC SHOCK	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
SHINGLES	Endocrine disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
SHORTNESS OF BREATH	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
SHORTNESS OF BREATH	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG00019 events17 affected1,723 at risk EG00126 events22 affected1,722 at risk
SHOT	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
SHOULDER INJURY	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0013 events2 affected1,722 at risk
SHOULDER PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
SHOULDER SURGERY	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
SICCA SYNDROME	Immune system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
SICK SINUS SYNDROME	Cardiac disorders	Systematic Assessment	EG0002 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
SINUS CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
SINUS NODE DISEASE	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
SINUSITIS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
SKIN CANCER	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
SKIN CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0015 events5 affected1,722 at risk
SKIN DISEASE	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
SKIN LACERATION	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
SKIN LACERATION	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
SKIN LESION	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
SKULL FRACTURE	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
SMALL BOWEL OBSTRUCTION	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
SPINAL STENOSIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
SPINAL STENOSIS	Nervous system disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
SPINAL STENOSIS	Surgical and medical procedures	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
SPINAL SURGERY	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
STENT GRAFT	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
STENT RESTENOSIS	Surgical and medical procedures	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
STERNUM DIASTASIS	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
STOMACH CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
STROKE	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0013 events3 affected1,722 at risk
STROKE	Nervous system disorders	Systematic Assessment	EG00065 events57 affected1,723 at risk EG00180 events71 affected1,722 at risk
STROKE	Surgical and medical procedures	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
SUBUNGUAL AND THECAL WHITLOW PANARICIUM OF THE LEFT HAND	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
SUPRATHERAPEUTIC INR	Blood and lymphatic system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
SURGICAL PROCEDURE	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
SYNCOPE	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
SYNCOPE	Endocrine disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
SYNCOPE	General disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
SYNCOPE	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
SYNCOPE	Nervous system disorders	Systematic Assessment	EG00030 events28 affected1,723 at risk EG00124 events21 affected1,722 at risk
TACHYCARDIA	Cardiac disorders	Systematic Assessment	EG0007 events7 affected1,723 at risk EG0015 events5 affected1,722 at risk
TEE	Surgical and medical procedures	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
THROAT CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
THROMBOEMBOLISM	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
THROMBOEMBOLISM	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0005 events3 affected1,723 at risk EG0011 events1 affected1,722 at risk
THROMBOEMBOLISM	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
THROMBOSIS	Vascular disorders	Systematic Assessment	EG0003 events2 affected1,723 at risk EG0013 events1 affected1,722 at risk
THYROIDECTOMY	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
TOE AMPUTATION	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
TOE AMPUTATION	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
TOOTH ABSCESS	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
TOOTHACHE	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
TOXIC ALLERGIC ALVEOLITIS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
TOXIC PNEUMONITIS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
TRANSIENT ISCHEMIC ATTACK	Cardiac disorders	Systematic Assessment	EG0002 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
TRANSIENT ISCHEMIC ATTACK	Nervous system disorders	Systematic Assessment	EG0008 events7 affected1,723 at risk EG0019 events8 affected1,722 at risk
TRANSURETHRAL PROSTATIC RESECTION	Surgical and medical procedures	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
TRAUMA	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
TREMOR	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0013 events3 affected1,722 at risk
TRICUSPID REGURGITATION	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
TUMOR REMOVAL	Surgical and medical procedures	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
ULCER	Gastrointestinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
ULCER	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
ULCER	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
ULCER	Vascular disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
UPPER RESPIRATORY INFECTION	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events1 affected1,722 at risk
UPPER RESPIRATORY INFECTION	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0014 events4 affected1,722 at risk
URETER STONE	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
URETHRITIS	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
URINARY INCONTINENCE	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
URINARY RETENTION	Renal and urinary disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0012 events2 affected1,722 at risk
URINARY TRACT INFECTION	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
URINARY TRACT INFECTION	Renal and urinary disorders	Systematic Assessment	EG00022 events16 affected1,723 at risk EG00118 events18 affected1,722 at risk
URINARY TRACT STONES	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
URTICARIA	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
UTERINE CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
UTERINE PROLAPSE	Reproductive system and breast disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
UTERINE TUMOR	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
VAGINITIS	Reproductive system and breast disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
VALVE REPLACEMENT	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
VALVE REPLACEMENT	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
VARICOSE VEINS	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
VENOUS INSUFFICIENCY	Vascular disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
VENOUS STASIS	Vascular disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
VENTRICULAR FIBRILLATION	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0013 events3 affected1,722 at risk
VERTEBROBASILAR INSUFFICIENCY	Nervous system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
VERTIGO	Ear and labyrinth disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
VERTIGO	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0011 events1 affected1,722 at risk
VISION CHANGES	Eye disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
VOLUME OVERLOAD	Vascular disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
VOMITING	Gastrointestinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
WARFARIN ALLERGIC REACTION	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
WARFARIN OVERDOSE	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
WEAKNESS	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0011 events1 affected1,722 at risk
WEAKNESS	General disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0017 events7 affected1,722 at risk
WEAKNESS	Nervous system disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0011 events1 affected1,722 at risk
WEIGHT GAIN	Metabolism and nutrition disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk
WORSENING HF	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events1 affected1,722 at risk
WOUND INFECTION	Infections and infestations	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0013 events3 affected1,722 at risk
XERODERMA	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0010 events0 affected1,722 at risk

Other Adverse Events

Term	Organ System	Assessment Type	Statistical Information
ABDOMINAL PAIN	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
ABDOMINAL PAIN	Gastrointestinal disorders	Systematic Assessment	EG00031 events28 affected1,723 at risk EG00134 events31 affected1,722 at risk
ABDOMINAL PAIN	Hepatobiliary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
ABDOMINAL PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0004 events3 affected1,723 at risk EG0016 events6 affected1,722 at risk
ABNORMAL BMP	General disorders	Systematic Assessment	EG0009 events5 affected1,723 at risk EG0011 events1 affected1,722 at risk
ABNORMAL VAGINAL BLEEDING	Reproductive system and breast disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0013 events3 affected1,722 at risk
ABSCESS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
ACTINIC KERATOSIS	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
ACUTE RESPIRATORY DISEASE	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG00017 events15 affected1,723 at risk EG0019 events9 affected1,722 at risk
ALLERGY	Immune system disorders	Systematic Assessment	EG00012 events11 affected1,723 at risk EG00112 events11 affected1,722 at risk
ALTERED MENTAL STATUS	Nervous system disorders	Systematic Assessment	EG0009 events9 affected1,723 at risk EG00112 events12 affected1,722 at risk
ANEMIA	Blood and lymphatic system disorders	Systematic Assessment	EG00048 events44 affected1,723 at risk EG00145 events41 affected1,722 at risk
ANEMIA	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
ANEURYSM	Cardiac disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0010 events0 affected1,722 at risk
ANGINA	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
ANGIOGRAPHY	Surgical and medical procedures	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
ANGIOPATHY	Vascular disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
ANKLE INJURY	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0014 events4 affected1,722 at risk
ANXIETY	Nervous system disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0011 events1 affected1,722 at risk
ANXIETY	Psychiatric disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0014 events4 affected1,722 at risk
ARM INJURY	General disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
ARM INJURY	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG00015 events14 affected1,723 at risk EG00110 events10 affected1,722 at risk
ARRHYTHMIA	Cardiac disorders	Systematic Assessment	EG00018 events16 affected1,723 at risk EG00113 events10 affected1,722 at risk
ARTERIAL STENOSIS	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
ARTHRALGIA	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0005 events4 affected1,723 at risk EG00114 events8 affected1,722 at risk
ARTHRITIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG00012 events11 affected1,723 at risk EG00110 events10 affected1,722 at risk
ASTHENIA	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0013 events3 affected1,722 at risk
ASTHMA	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0009 events7 affected1,723 at risk EG0019 events9 affected1,722 at risk
ATAXIA	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
ATAXIA	Nervous system disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0015 events5 affected1,722 at risk
ATHEROSCLEROSIS	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0014 events3 affected1,722 at risk
ATHEROSCLEROSIS	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
ATHEROSCLEROSIS	Vascular disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0014 events4 affected1,722 at risk
ATRIAL FIBRILLATION	Cardiac disorders	Systematic Assessment	EG000123 events85 affected1,723 at risk EG00197 events74 affected1,722 at risk
ATRIAL FLUTTER	Cardiac disorders	Systematic Assessment	EG0006 events5 affected1,723 at risk EG0019 events7 affected1,722 at risk
AV BLOCK	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
BACK INJURY	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
BACK PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG00074 events64 affected1,723 at risk EG00176 events67 affected1,722 at risk
BLADDER CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0011 events1 affected1,722 at risk
BLADDER TUMOR	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
BLEEDING	Blood and lymphatic system disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
BLEEDING IN EYE	Eye disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0018 events7 affected1,722 at risk
BLOOD IN STOOL	Gastrointestinal disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0010 events0 affected1,722 at risk
BLURRED VISION	Eye disorders	Systematic Assessment	EG0009 events9 affected1,723 at risk EG0015 events5 affected1,722 at risk
BODY ACHES	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0010 events0 affected1,722 at risk
BODY PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG00011 events9 affected1,723 at risk EG0019 events9 affected1,722 at risk
BRADYCARDIA	Cardiac disorders	Systematic Assessment	EG0008 events8 affected1,723 at risk EG00122 events20 affected1,722 at risk
BREAST CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0011 events1 affected1,722 at risk
BREAST PAIN	Reproductive system and breast disorders	Systematic Assessment	EG0005 events5 affected1,723 at risk EG00118 events18 affected1,722 at risk
BREAST TENDERNESS	Reproductive system and breast disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
BRONCHITIS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG00069 events64 affected1,723 at risk EG00175 events63 affected1,722 at risk
BRONCHOSPASM	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0008 events6 affected1,723 at risk EG0012 events2 affected1,722 at risk
BRUISE	Blood and lymphatic system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
BRUISE	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0007 events5 affected1,723 at risk EG0011 events1 affected1,722 at risk
BRUISE	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0009 events9 affected1,723 at risk EG00112 events11 affected1,722 at risk
BUNDLE BRANCH BLOCK	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
BURSITIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0008 events8 affected1,723 at risk EG0012 events2 affected1,722 at risk
BUTTOCK PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0014 events4 affected1,722 at risk
C-DIFF INFECTION	Infections and infestations	Systematic Assessment	EG0005 events5 affected1,723 at risk EG0010 events0 affected1,722 at risk
CANCER REMOVAL	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
CARDIOVERSION	Cardiac disorders	Systematic Assessment	EG0005 events4 affected1,723 at risk EG0012 events2 affected1,722 at risk
CARPEL TUNNEL RELEASE	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
CARPEL TUNNEL SYNDROME	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
CARPEL TUNNEL SYNDROME	Nervous system disorders	Systematic Assessment	EG0005 events3 affected1,723 at risk EG0011 events1 affected1,722 at risk
CATARACTS	Eye disorders	Systematic Assessment	EG00021 events17 affected1,723 at risk EG00121 events18 affected1,722 at risk
CELLULITIS	Infections and infestations	Systematic Assessment	EG00011 events11 affected1,723 at risk EG0012 events2 affected1,722 at risk
CELLULITIS	Skin and subcutaneous tissue disorders	Systematic Assessment	EG00020 events20 affected1,723 at risk EG00122 events18 affected1,722 at risk
CHEMOTHERAPY	Surgical and medical procedures	Systematic Assessment	EG0003 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
CHEST CONGESTION	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0013 events3 affected1,722 at risk
CHEST PAIN	Cardiac disorders	Systematic Assessment	EG000130 events102 affected1,723 at risk EG001102 events80 affected1,722 at risk
CHEST PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0008 events8 affected1,723 at risk EG00112 events11 affected1,722 at risk
CHILLS	General disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0013 events2 affected1,722 at risk
CHOLECYSTITIS	Hepatobiliary disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0015 events5 affected1,722 at risk
CHRONIC OBSTRUCTIVE PULMONARY DISEASE	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG00015 events14 affected1,723 at risk EG00112 events10 affected1,722 at risk
CLAUDICATION	Vascular disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
COLD EXTREMITIES	Vascular disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0011 events1 affected1,722 at risk
COLD SYMPTOMS	General disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0010 events0 affected1,722 at risk
COLITIS	Gastrointestinal disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0014 events4 affected1,722 at risk
COLONOSCOPY	Surgical and medical procedures	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
CONCUSSION	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
CONFUSION	Nervous system disorders	Systematic Assessment	EG00010 events9 affected1,723 at risk EG0015 events5 affected1,722 at risk
CONJUCTIVITIS	Eye disorders	Systematic Assessment	EG0005 events5 affected1,723 at risk EG0018 events8 affected1,722 at risk
CONSTIPATION	Gastrointestinal disorders	Systematic Assessment	EG00026 events25 affected1,723 at risk EG00131 events28 affected1,722 at risk
CORONARY ARTERY DISEASE	Cardiac disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0010 events0 affected1,722 at risk
COUGH	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG00053 events44 affected1,723 at risk EG00147 events44 affected1,722 at risk
CYST	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG00014 events14 affected1,723 at risk EG00119 events18 affected1,722 at risk
CYST	Renal and urinary disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
CYSTOSCOPY	Renal and urinary disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
DECREASED APPETITE	Gastrointestinal disorders	Systematic Assessment	EG0008 events8 affected1,723 at risk EG00110 events10 affected1,722 at risk
DECREASED APPETITE	Metabolism and nutrition disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
DEEP VEIN THROMBOSIS	Vascular disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0012 events2 affected1,722 at risk
DEHYDRATION	Gastrointestinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
DEHYDRATION	General disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG00113 events13 affected1,722 at risk
DEMENTIA	Nervous system disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
DENTAL ABSCESS	Infections and infestations	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
DEPRESSION	Psychiatric disorders	Systematic Assessment	EG00016 events16 affected1,723 at risk EG00120 events20 affected1,722 at risk
DERMATITIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
DERMATITIS	Skin and subcutaneous tissue disorders	Systematic Assessment	EG00029 events27 affected1,723 at risk EG00126 events25 affected1,722 at risk
DESTABILIZATION OF BLOOD PRESSURE	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
DEVICE CHANGE	Cardiac disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0014 events4 affected1,722 at risk
DIABETES	Endocrine disorders	Systematic Assessment	EG00040 events37 affected1,723 at risk EG00142 events38 affected1,722 at risk
DIABETES	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
DIAPHORESIS	General disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
DIARRHEA	Gastrointestinal disorders	Systematic Assessment	EG00083 events74 affected1,723 at risk EG00188 events79 affected1,722 at risk
DIVERTICULITIS	Gastrointestinal disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0012 events2 affected1,722 at risk
DIZZINESS	Cardiac disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0012 events2 affected1,722 at risk
DIZZINESS	General disorders	Systematic Assessment	EG00044 events35 affected1,723 at risk EG00135 events34 affected1,722 at risk
DIZZINESS	Nervous system disorders	Systematic Assessment	EG00070 events54 affected1,723 at risk EG00175 events64 affected1,722 at risk
DORSOPATHY	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0011 events1 affected1,722 at risk
DROWSINESS	Nervous system disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0013 events3 affected1,722 at risk
DRY EYES	Eye disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
DUODENITIS	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
DYSLIPIDEMIA	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
DYSLIPIDEMIA	General disorders	Systematic Assessment	EG00018 events16 affected1,723 at risk EG00113 events13 affected1,722 at risk
DYSLIPIDEMIA	Metabolism and nutrition disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0010 events0 affected1,722 at risk
DYSPEPSIA	Gastrointestinal disorders	Systematic Assessment	EG0005 events4 affected1,723 at risk EG0012 events2 affected1,722 at risk
DYSPHAGIA	Gastrointestinal disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0014 events4 affected1,722 at risk
DYSPNEA	Cardiac disorders	Systematic Assessment	EG00044 events37 affected1,723 at risk EG00132 events31 affected1,722 at risk
DYSPNEA	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0013 events3 affected1,722 at risk
DYSURIA	Renal and urinary disorders	Systematic Assessment	EG0007 events7 affected1,723 at risk EG0016 events6 affected1,722 at risk
EAR ACHE	Ear and labyrinth disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
EAR INFECTION	Ear and labyrinth disorders	Systematic Assessment	EG0007 events7 affected1,723 at risk EG0016 events6 affected1,722 at risk
EAR INFECTION	Infections and infestations	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0011 events1 affected1,722 at risk
EAR PAIN	Ear and labyrinth disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0013 events3 affected1,722 at risk
EDEMA	Cardiac disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0014 events4 affected1,722 at risk
EDEMA	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0012 events2 affected1,722 at risk
ELEVATED BILIRUBIN	Hepatobiliary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
ELEVATED BNP	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
ELEVATED BUN	Renal and urinary disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0014 events4 affected1,722 at risk
ELEVATED CARDIAC ENZYMES	Cardiac disorders	Systematic Assessment	EG0005 events5 affected1,723 at risk EG0019 events9 affected1,722 at risk
ELEVATED CREATININE	Renal and urinary disorders	Systematic Assessment	EG00050 events47 affected1,723 at risk EG00177 events60 affected1,722 at risk
ELEVATED INR	Blood and lymphatic system disorders	Systematic Assessment	EG0003 events2 affected1,723 at risk EG0014 events4 affected1,722 at risk
ELEVATED LIVER ENZYMES	Hepatobiliary disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0016 events5 affected1,722 at risk
ELEVATED LIVER ENZYMES	Renal and urinary disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events1 affected1,722 at risk
ELEVATED PSA	Reproductive system and breast disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
EMOTIONAL LABILITY	Psychiatric disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0014 events4 affected1,722 at risk
ENCEPHALOPATHY	Nervous system disorders	Systematic Assessment	EG0008 events8 affected1,723 at risk EG0016 events6 affected1,722 at risk
EPIGASTRIC PAIN	Gastrointestinal disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0011 events1 affected1,722 at risk
EPISTAXIS	Vascular disorders	Systematic Assessment	EG00021 events21 affected1,723 at risk EG00127 events19 affected1,722 at risk
ERECTILE DYSFUNCTION	Reproductive system and breast disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0013 events3 affected1,722 at risk
ERYTHROCYTOSIS	Blood and lymphatic system disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
ESOPHAGITIS	Gastrointestinal disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0010 events0 affected1,722 at risk
EXTRASYSTOLE	Cardiac disorders	Systematic Assessment	EG0007 events7 affected1,723 at risk EG0018 events7 affected1,722 at risk
EYE PAIN	Eye disorders	Systematic Assessment	EG0003 events2 affected1,723 at risk EG0014 events3 affected1,722 at risk
EYELID CYSTS	Eye disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
FALL	Injury, poisoning and procedural complications	Systematic Assessment	EG0005 events4 affected1,723 at risk EG0013 events3 affected1,722 at risk
FALL	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG00012 events12 affected1,723 at risk EG00117 events15 affected1,722 at risk
FALL	Nervous system disorders	Systematic Assessment	EG0007 events4 affected1,723 at risk EG0013 events2 affected1,722 at risk
FATIGUE	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
FATIGUE	General disorders	Systematic Assessment	EG00018 events17 affected1,723 at risk EG0017 events7 affected1,722 at risk
FATTY HEPATOSIS	Hepatobiliary disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
FEVER	General disorders	Systematic Assessment	EG0008 events8 affected1,723 at risk EG0013 events3 affected1,722 at risk
FEVER	Infections and infestations	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0015 events5 affected1,722 at risk
FLATULENCE	Gastrointestinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
FLU LIKE SYMPTOMS	General disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
FLUID RETENTION	General disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
FOOT INJURY	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0013 events2 affected1,722 at risk
FOOT PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0008 events6 affected1,723 at risk EG0017 events7 affected1,722 at risk
FRACTURE	Injury, poisoning and procedural complications	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0013 events3 affected1,722 at risk
FRACTURE	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG00034 events33 affected1,723 at risk EG00130 events28 affected1,722 at risk
GALLSTONES	Hepatobiliary disorders	Systematic Assessment	EG0005 events5 affected1,723 at risk EG00110 events7 affected1,722 at risk
GASTRIC REFLUX	Gastrointestinal disorders	Systematic Assessment	EG0007 events7 affected1,723 at risk EG0013 events3 affected1,722 at risk
GASTRITIS	Gastrointestinal disorders	Systematic Assessment	EG00059 events58 affected1,723 at risk EG00159 events52 affected1,722 at risk
GASTROENTERITIS	Gastrointestinal disorders	Systematic Assessment	EG00014 events14 affected1,723 at risk EG0016 events6 affected1,722 at risk
GI BLEED	Gastrointestinal disorders	Systematic Assessment	EG0008 events8 affected1,723 at risk EG00111 events11 affected1,722 at risk
GI DISTRESS	Gastrointestinal disorders	Systematic Assessment	EG0006 events6 affected1,723 at risk EG0017 events7 affected1,722 at risk
GLAUCOMA	Eye disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0013 events3 affected1,722 at risk
GOITER	Endocrine disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0017 events7 affected1,722 at risk
GONITIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0014 events3 affected1,722 at risk
GOUT	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG00048 events36 affected1,723 at risk EG00138 events34 affected1,722 at risk
GYNECOMASTIA	Endocrine disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0016 events6 affected1,722 at risk
GYNECOMASTIA	Reproductive system and breast disorders	Systematic Assessment	EG0008 events7 affected1,723 at risk EG00145 events44 affected1,722 at risk
HAIR LOSS	Immune system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0013 events3 affected1,722 at risk
HAND INJURY	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0013 events3 affected1,722 at risk
HAND PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0014 events3 affected1,722 at risk
HAY FEVER	Immune system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
HEAD INJURY	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
HEADACHE	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
HEADACHE	Nervous system disorders	Systematic Assessment	EG000113 events90 affected1,723 at risk EG00198 events84 affected1,722 at risk
HEARING LOSS	Ear and labyrinth disorders	Systematic Assessment	EG0009 events8 affected1,723 at risk EG0014 events4 affected1,722 at risk
HEART FAILURE	Cardiac disorders	Systematic Assessment	EG000174 events135 affected1,723 at risk EG001150 events121 affected1,722 at risk
HEART VALVE CALCIFICATION	Cardiac disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0010 events0 affected1,722 at risk
HEARTBURN	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
HEARTBURN	Gastrointestinal disorders	Systematic Assessment	EG0007 events7 affected1,723 at risk EG0017 events7 affected1,722 at risk
HEMATEMESIS	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
HEMATOMA	Blood and lymphatic system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0013 events3 affected1,722 at risk
HEMATOMA	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0013 events1 affected1,722 at risk
HEMATURIA	Blood and lymphatic system disorders	Systematic Assessment	EG0003 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
HEMATURIA	Renal and urinary disorders	Systematic Assessment	EG00010 events10 affected1,723 at risk EG00111 events11 affected1,722 at risk
HEMOPTYSIS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0016 events5 affected1,722 at risk
HEMORRHOIDS	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0013 events3 affected1,722 at risk
HEMORRHOIDS	Vascular disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
HERNIA	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG00014 events13 affected1,723 at risk EG0016 events6 affected1,722 at risk
HERNIA	Surgical and medical procedures	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
HERPES SIMPLEX	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
HIP PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG00010 events10 affected1,723 at risk EG00120 events17 affected1,722 at risk
HOARSENESS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
HOT FLASHES	Endocrine disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
HYPERCALCEMIA	General disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
HYPERCALCEMIA	Renal and urinary disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
HYPEREMIA	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
HYPERGLYCEMIA	Endocrine disorders	Systematic Assessment	EG00029 events26 affected1,723 at risk EG00125 events21 affected1,722 at risk
HYPERKALEMIA	Cardiac disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
HYPERKALEMIA	Endocrine disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
HYPERKALEMIA	Metabolism and nutrition disorders	Systematic Assessment	EG0004 events3 affected1,723 at risk EG0016 events5 affected1,722 at risk
HYPERKALEMIA	Renal and urinary disorders	Systematic Assessment	EG000109 events96 affected1,723 at risk EG001273 events226 affected1,722 at risk
HYPERTENSIC CRISIS	Cardiac disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0010 events0 affected1,722 at risk
HYPERTENSION	Cardiac disorders	Systematic Assessment	EG000265 events145 affected1,723 at risk EG001219 events113 affected1,722 at risk
HYPERTENSION	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0010 events0 affected1,722 at risk
HYPERTHERMIA	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
HYPERTHYROIDISM	Endocrine disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0013 events3 affected1,722 at risk
HYPERURICEMIA	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0015 events4 affected1,722 at risk
HYPERVOLEMIA	Cardiac disorders	Systematic Assessment	EG0009 events6 affected1,723 at risk EG00114 events7 affected1,722 at risk
HYPOGLYCEMIA	Endocrine disorders	Systematic Assessment	EG00027 events19 affected1,723 at risk EG0019 events9 affected1,722 at risk
HYPOKALEMIA	Metabolism and nutrition disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
HYPOKALEMIA	Renal and urinary disorders	Systematic Assessment	EG00038 events29 affected1,723 at risk EG00117 events13 affected1,722 at risk
HYPONATREMIA	Metabolism and nutrition disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0013 events3 affected1,722 at risk
HYPONATREMIA	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG00112 events10 affected1,722 at risk
HYPOTENSION	Cardiac disorders	Systematic Assessment	EG00059 events52 affected1,723 at risk EG00190 events71 affected1,722 at risk
HYPOTHYROIDISM	Endocrine disorders	Systematic Assessment	EG0008 events8 affected1,723 at risk EG00115 events15 affected1,722 at risk
HYPOXIA	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
INCREASED OF TSH	Endocrine disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
INFECTION	Infections and infestations	Systematic Assessment	EG0005 events5 affected1,723 at risk EG0018 events8 affected1,722 at risk
INFLUENZA	General disorders	Systematic Assessment	EG0006 events6 affected1,723 at risk EG0012 events2 affected1,722 at risk
INFLUENZA	Infections and infestations	Systematic Assessment	EG00082 events71 affected1,723 at risk EG00180 events70 affected1,722 at risk
INFLUENZA	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
INGROWN TOENAIL	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
INSOMNIA	Nervous system disorders	Systematic Assessment	EG00055 events39 affected1,723 at risk EG00146 events29 affected1,722 at risk
IRON DEFICIENCY	Blood and lymphatic system disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
IRON OVERLOAD	Blood and lymphatic system disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
KIDNEY DISEASE	Renal and urinary disorders	Systematic Assessment	EG00076 events68 affected1,723 at risk EG001182 events135 affected1,722 at risk
KIDNEY STONE	Renal and urinary disorders	Systematic Assessment	EG00010 events8 affected1,723 at risk EG0016 events5 affected1,722 at risk
KNEE INJURY	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0014 events4 affected1,722 at risk
KNEE PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG00012 events12 affected1,723 at risk EG00122 events20 affected1,722 at risk
LABYRINTHITIS	Ear and labyrinth disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0013 events3 affected1,722 at risk
LACTOSE INTOLERANCE	Gastrointestinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
LEG CLAUDICATION	Vascular disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
LEG EDEMA	Cardiac disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0010 events0 affected1,722 at risk
LEG INJURY	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
LEG PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG00031 events30 affected1,723 at risk EG00130 events29 affected1,722 at risk
LEUKOCYTOSIS	Blood and lymphatic system disorders	Systematic Assessment	EG0005 events5 affected1,723 at risk EG0012 events2 affected1,722 at risk
LIMB EDEMA	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
LIPOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0013 events2 affected1,722 at risk
LOW HEMOGLOBIN	Blood and lymphatic system disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
LOWER EXTREMITY EDEMA	Cardiac disorders	Systematic Assessment	EG00044 events40 affected1,723 at risk EG00141 events36 affected1,722 at risk
LOWER EXTREMITY EDEMA	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
LOWER EXTREMITY EDEMA	Vascular disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0013 events3 affected1,722 at risk
LUNG CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
LUNG MASS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
MACULAR DEGENERATION	Eye disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
MEMORY LOSS	Nervous system disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0019 events7 affected1,722 at risk
MOUTH PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
MUSCLE INJURY	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
MUSCLE PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0006 events6 affected1,723 at risk EG0016 events6 affected1,722 at risk
MUSCLE SPASM	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0013 events3 affected1,722 at risk
MYOCARDIAL INFARCTION	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
NASAL CONGESTION	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0014 events4 affected1,722 at risk
NAUSEA	Gastrointestinal disorders	Systematic Assessment	EG00037 events34 affected1,723 at risk EG00157 events54 affected1,722 at risk
NECK PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0005 events5 affected1,723 at risk EG0017 events7 affected1,722 at risk
NEURALGIA	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
NEUROPATHY	Nervous system disorders	Systematic Assessment	EG0007 events7 affected1,723 at risk EG0014 events4 affected1,722 at risk
NEUROSIS	Psychiatric disorders	Systematic Assessment	EG00021 events13 affected1,723 at risk EG0018 events6 affected1,722 at risk
NOCTURIA	Renal and urinary disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
OLIGURIA	Renal and urinary disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
ONYCHOMYCOSIS	Infections and infestations	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
ORTHOPNEA	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
OSTEOARTHRITIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG00014 events14 affected1,723 at risk EG00127 events26 affected1,722 at risk
OSTEOCHONDROSIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG00010 events10 affected1,723 at risk EG00115 events14 affected1,722 at risk
OSTEOPOROSIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0012 events2 affected1,722 at risk
OTITIS	Ear and labyrinth disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
PALPITATIONS	Cardiac disorders	Systematic Assessment	EG00029 events26 affected1,723 at risk EG00126 events25 affected1,722 at risk
PARAGEUSIA	Gastrointestinal disorders	Systematic Assessment	EG0003 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
PARASTHESIA	Nervous system disorders	Systematic Assessment	EG00024 events20 affected1,723 at risk EG00126 events23 affected1,722 at risk
PARKINSON'S DISEASE	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
PERICARDITIS	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
PERIPHERAL ARTERIAL DISEASE	Vascular disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0013 events3 affected1,722 at risk
PERIPHERAL EDEMA	Cardiac disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0011 events1 affected1,722 at risk
PHARYNGITIS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0005 events5 affected1,723 at risk EG0013 events3 affected1,722 at risk
PLEURAL EFFUSION	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0017 events6 affected1,722 at risk
PNEUMONIA	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG00032 events31 affected1,723 at risk EG00149 events44 affected1,722 at risk
POLYPS	Gastrointestinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
POLYPS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0006 events6 affected1,723 at risk EG0019 events9 affected1,722 at risk
POLYURIA	Renal and urinary disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0014 events4 affected1,722 at risk
PROSTATE CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0014 events3 affected1,722 at risk
PROSTATIC HYPERPLASIA	Reproductive system and breast disorders	Systematic Assessment	EG0006 events6 affected1,723 at risk EG0016 events6 affected1,722 at risk
PROTEINURIA	Renal and urinary disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0014 events4 affected1,722 at risk
PRURITIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
PRURITIS	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0009 events8 affected1,723 at risk EG00114 events14 affected1,722 at risk
PSORIASIS	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
PULMONARY CONGESTION	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0013 events3 affected1,722 at risk
PULMONARY EDEMA	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0012 events2 affected1,722 at risk
PULMONARY EMBOLISM	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0015 events4 affected1,722 at risk
PULMONARY FIBROSIS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
PULMONARY OVERLOAD	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0014 events3 affected1,722 at risk
PURITIS	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0005 events3 affected1,723 at risk EG0011 events1 affected1,722 at risk
PYELONEPHRITIS	Renal and urinary disorders	Systematic Assessment	EG0008 events8 affected1,723 at risk EG0019 events9 affected1,722 at risk
RADICULITIS	Nervous system disorders	Systematic Assessment	EG0008 events7 affected1,723 at risk EG0018 events8 affected1,722 at risk
RASH	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
RENAL FAILURE	Renal and urinary disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
RESPIRATORY FAILURE	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
RESPIRATORY TRACT INFECTION	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0007 events7 affected1,723 at risk EG0015 events5 affected1,722 at risk
RESTLESS LEG SYNDROME	Nervous system disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
RETINOPATHY	Eye disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
RHINITIS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0007 events7 affected1,723 at risk EG00112 events10 affected1,722 at risk
RIB PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0013 events3 affected1,722 at risk
SCIATICA	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
SCIATICA	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0017 events7 affected1,722 at risk
SEASONAL ALLERGIES	Immune system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
SEIZURE	Nervous system disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0013 events3 affected1,722 at risk
SEPSIS	Infections and infestations	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0010 events0 affected1,722 at risk
SEXUALLY TRANSMITTED DISEASE	Infections and infestations	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
SHINGLES	Infections and infestations	Systematic Assessment	EG0007 events7 affected1,723 at risk EG00110 events10 affected1,722 at risk
SHORTNESS OF BREATH	Cardiac disorders	Systematic Assessment	EG0004 events2 affected1,723 at risk EG0014 events3 affected1,722 at risk
SHORTNESS OF BREATH	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG00040 events34 affected1,723 at risk EG00130 events27 affected1,722 at risk
SHOULDER INJURY	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
SHOULDER INJURY	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0014 events4 affected1,722 at risk
SHOULDER PAIN	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG00014 events14 affected1,723 at risk EG00110 events9 affected1,722 at risk
SICK SINUS SYNDROME	Cardiac disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0014 events4 affected1,722 at risk
SINUSITIS	Infections and infestations	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0013 events3 affected1,722 at risk
SINUSITIS	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG00021 events19 affected1,723 at risk EG00117 events14 affected1,722 at risk
SKIN CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG00022 events17 affected1,723 at risk EG00115 events14 affected1,722 at risk
SKIN LACERATION	Injury, poisoning and procedural complications	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
SKIN LACERATION	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0011 events1 affected1,722 at risk
SKIN LACERATION	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0016 events6 affected1,722 at risk
SKIN LESION	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0013 events3 affected1,722 at risk
SKIN WOUND	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
SLEEP APNEA	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG00013 events13 affected1,723 at risk EG0019 events9 affected1,722 at risk
SLEEP DISTURBANCE	Nervous system disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
SORE THROAT	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
SORE THROAT	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0013 events3 affected1,722 at risk
SPINAL STENOSIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
STENOSING TENOSYNOVITIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0012 events2 affected1,722 at risk
STOMACH ULCER	Gastrointestinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
STROKE	Nervous system disorders	Systematic Assessment	EG00011 events10 affected1,723 at risk EG00111 events8 affected1,722 at risk
SUPRATHERAPEUTIC INR	Blood and lymphatic system disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0012 events1 affected1,722 at risk
SWEATING	General disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0013 events3 affected1,722 at risk
SYNCOPE	Nervous system disorders	Systematic Assessment	EG00027 events24 affected1,723 at risk EG00128 events28 affected1,722 at risk
TACHYCARDIA	Cardiac disorders	Systematic Assessment	EG00029 events20 affected1,723 at risk EG00125 events22 affected1,722 at risk
TENDONITIS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0013 events3 affected1,722 at risk
THROMBOCYTOPENIA	Blood and lymphatic system disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0013 events2 affected1,722 at risk
THROMBOPHLEBITIS	Vascular disorders	Systematic Assessment	EG0006 events6 affected1,723 at risk EG0012 events2 affected1,722 at risk
THRUSH	Infections and infestations	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0011 events1 affected1,722 at risk
THYROID NODULE	Endocrine disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
THYROID NODULE	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
TINNITUS	Ear and labyrinth disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0015 events5 affected1,722 at risk
TMJ DISORDER	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
TONGUE LESION	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
TONSILLITIS	Infections and infestations	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
TOOTH ABSCESS	Infections and infestations	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
TOOTH EXTRACTION	Surgical and medical procedures	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0013 events3 affected1,722 at risk
TOOTHACHE	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG00013 events12 affected1,723 at risk EG0019 events8 affected1,722 at risk
TRANSIENT ISCHEMIC ATTACK	Nervous system disorders	Systematic Assessment	EG00014 events11 affected1,723 at risk EG0013 events3 affected1,722 at risk
TREMOR	Nervous system disorders	Systematic Assessment	EG0005 events5 affected1,723 at risk EG0015 events5 affected1,722 at risk
ULCER	Gastrointestinal disorders	Systematic Assessment	EG0004 events4 affected1,723 at risk EG0018 events8 affected1,722 at risk
ULCER	Metabolism and nutrition disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
ULCER	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0006 events5 affected1,723 at risk EG0013 events3 affected1,722 at risk
ULCER	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0007 events6 affected1,723 at risk EG0014 events4 affected1,722 at risk
ULCER	Vascular disorders	Systematic Assessment	EG0004 events3 affected1,723 at risk EG0013 events2 affected1,722 at risk
UPPER RESPIRATORY INFECTION	Infections and infestations	Systematic Assessment	EG0007 events7 affected1,723 at risk EG0016 events4 affected1,722 at risk
UPPER RESPIRATORY INFECTION	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG00090 events78 affected1,723 at risk EG00198 events86 affected1,722 at risk
URETHRITIS	Gastrointestinal disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
URETHRITIS	Renal and urinary disorders	Systematic Assessment	EG0000 events0 affected1,723 at risk EG0012 events2 affected1,722 at risk
URINARY HESITANCY	Renal and urinary disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
URINARY INCONTINENCE	Renal and urinary disorders	Systematic Assessment	EG0006 events5 affected1,723 at risk EG0017 events7 affected1,722 at risk
URINARY RETENTION	Renal and urinary disorders	Systematic Assessment	EG0005 events5 affected1,723 at risk EG00110 events10 affected1,722 at risk
URINARY TRACT INFECTION	Renal and urinary disorders	Systematic Assessment	EG00084 events68 affected1,723 at risk EG00174 events60 affected1,722 at risk
URINARY TRACT STONES	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
URINARY URGENCY	Renal and urinary disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
URTICARIA	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0019 events8 affected1,722 at risk
VARICOSE VEINS	Vascular disorders	Systematic Assessment	EG0005 events5 affected1,723 at risk EG00110 events8 affected1,722 at risk
VENOUS INSUFFICIENCY	Vascular disorders	Systematic Assessment	EG0004 events3 affected1,723 at risk EG00112 events10 affected1,722 at risk
VERTIGO	Ear and labyrinth disorders	Systematic Assessment	EG00020 events16 affected1,723 at risk EG00111 events11 affected1,722 at risk
VERTIGO	Nervous system disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
VISION CHANGES	Eye disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
VISION LOSS	Eye disorders	Systematic Assessment	EG0003 events3 affected1,723 at risk EG0015 events5 affected1,722 at risk
VITAMIN D DEFICIENCY	Metabolism and nutrition disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0013 events3 affected1,722 at risk
VOMITING	Gastrointestinal disorders	Systematic Assessment	EG00020 events20 affected1,723 at risk EG00121 events20 affected1,722 at risk
WEAKNESS	Cardiac disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
WEAKNESS	Gastrointestinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
WEAKNESS	General disorders	Systematic Assessment	EG00037 events35 affected1,723 at risk EG00153 events45 affected1,722 at risk
WEAKNESS	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0015 events5 affected1,722 at risk
WEAKNESS	Nervous system disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0012 events2 affected1,722 at risk
WEIGHT GAIN	Metabolism and nutrition disorders	Systematic Assessment	EG00017 events16 affected1,723 at risk EG00117 events15 affected1,722 at risk
WEIGHT LOSS	General disorders	Systematic Assessment	EG0001 events1 affected1,723 at risk EG0012 events2 affected1,722 at risk
WEIGHT LOSS	Metabolism and nutrition disorders	Systematic Assessment	EG0009 events8 affected1,723 at risk EG0017 events5 affected1,722 at risk
WHEEZING	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0010 events0 affected1,722 at risk
WOUND INFECTION	Infections and infestations	Systematic Assessment	EG0002 events2 affected1,723 at risk EG0011 events1 affected1,722 at risk
XEROSTOMIA	Gastrointestinal disorders	Systematic Assessment	EG0007 events7 affected1,723 at risk EG0016 events6 affected1,722 at risk

ID	Term
D002318	Cardiovascular Diseases
D006331	Heart Diseases
D006333	Heart Failure
D054144	Heart Failure, Diastolic

ID	Term
D007783	Lactones
D009930	Organic Chemicals
D011283	Pregnenes
D011278	Pregnanes
D013256	Steroids
D000072473	Fused-Ring Compounds
D011083	Polycyclic Compounds
D006727	Hormone Antagonists
D006730	Hormones, Hormone Substitutes, and Hormone Antagonists
D045505	Physiological Effects of Drugs
D020228	Pharmacologic Actions
D020164	Chemical Actions and Uses
D062865	Diuretics, Potassium Sparing
D004232	Diuretics
D045283	Natriuretic Agents

ID	Title	Description
BG000	Placebo	Placebo of spironolactone
BG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.
BG002	Total	Total of all reporting groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Placebo	Placebo of spironolactone			855	1,723	1,086	1,723
EG001	Spironolactone	Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.			835	1,722	1,152	1,722

ID	Term
D013148	Spironolactone
D000451	Mineralocorticoid Receptor Antagonists